Cognition Therapeutics (CGTX) Shares Outstanding (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Shares Outstanding data on file, last reported at $89.4 million in Q1 2026.

• Quarterly Shares Outstanding rose 44.18% year-over-year to $89.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.4 million (up 44.18% YoY) and the FY2025 annual result came in at $88.9 million, up 48.53% from the prior year.
• Shares Outstanding grew to $89.4 million in Q1 2026 per CGTX's latest filing, from $88.9 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $89.4 million in Q1 2026 and bottomed at $22.6 million in Q1 2022.
• The 5-year median for Shares Outstanding is $40.0 million (2024), against an average of $46.7 million.
• The widest annual swing landed in 2022, when Shares Outstanding soared 3934.92%; it then grew 10.95% in 2023.
• Tracing CGTX's Shares Outstanding over 5 years: stood at $29.0 million in 2022, then climbed by 10.95% to $32.2 million in 2023, then soared by 86.08% to $59.9 million in 2024, then jumped by 48.53% to $88.9 million in 2025, then advanced by 0.51% to $89.4 million in 2026.
• Per Business Quant, the three latest CGTX Shares Outstanding figures stand at $89.4 million (Q1 2026), $88.9 million (Q4 2025), and $88.3 million (Q3 2025).

Peer Comparison